{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:13Z","timestamp":1792782673390,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences GmbH","id":[{"id":"https:\/\/ror.org\/056546b03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of diffuse large B-cell lymphoma (DLBCL) but carries higher drug acquisition costs than autologous stem cell transplantation (autoSCT), while administration and follow-up costs remain underrepresented in economic evaluations and reimbursement decision-making. This study compares administration-related and subsequent treatment costs of CAR-T and autoSCT for DLBCL from the German statutory health insurance (SHI) perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A two-step analysis based on two German databases was performed. In step 1, SHI billing data (representing 5 million insured individuals, \u2259 8% of SHI) from 2020\u20132022 were analyzed longitudinally. Costs were divided into initial regime (IR) (all services except CAR-T drug acquisition) and a following regime (FR). In step 2, a cross-sectional analysis of all German inpatient cases from 2020\u20132023 (17 million cases\/year) assessed inpatient costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Step 1 included 12 CAR-T and 59 autoSCT patients. Median IR costs per patient were \u20ac61,703 (CAR-T) versus \u20ac55,802 (autoSCT), while FR costs were lower for CAR-T (\u20ac44,832 versus \u20ac69,453). Most frequently reported adverse events (any grade) for CAR-T versus autoSCT were: B-cell aplasia\/neutropenia (77% versus 64%), thrombocytopenia (38% versus 64%). Step 2 included 1,229 CAR-T and 2,239 autoSCT inpatient cases (2020\u20132023). Average LOS was comparable (27.3 versus 27.8 days), and average inpatient costs were lower for CAR-T (\u20ac13,991 versus \u20ac29,432).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although associated with higher IR costs, CAR-T therapy in DLBCL demonstrated lower inpatient and FR costs compared to autoSCT. This analysis focused on administration and follow-up costs, excluding drug acquisition costs, characterizing the economic burden beyond drug pricing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06628-0","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:15:04Z","timestamp":1790770504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Cost and Utilization Analysis of CAR-T Therapy and Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma in Germany: Insights from Statutory Health Insurance Billing and Nationwide Inpatient Data"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3246-1461","authenticated-orcid":false,"given":"Ann-Cathrine","family":"Froitzheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8918-1769","authenticated-orcid":false,"given":"Melina Sophie","family":"Kurte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lempfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6692-9560","authenticated-orcid":false,"given":"Katja","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-7490","authenticated-orcid":false,"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"14","key":"6628_CR2","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 141(14):1675\u20131684. https:\/\/doi.org\/10.1182\/blood.2022018730","journal-title":"Blood"},{"issue":"5","key":"6628_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Dehner C, Kim Y, Ogasawara K, Kostic A, Siddiqi T (2024) Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143(5):404\u2013416. https:\/\/doi.org\/10.1182\/blood.2023020854","journal-title":"Blood"},{"issue":"1","key":"6628_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann P, Heger J-M, Mahlich J, Papadimitrious MS, Riou S, Werner B (2023) Healthcare resource utilization and associated costs of german patients with diffuse large B-cell lymphoma: a retrospective health claims data analysis. Oncol Therapy 11(1):65\u201381. https:\/\/doi.org\/10.1007\/s40487-022-00211-6","journal-title":"Oncol Therapy"},{"issue":"10097","key":"6628_CR4","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Bl\u00fcmel M, Knieps F, B\u00e4rnighausen T (2017) Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet 390(10097):882\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(17)31280-1","journal-title":"Lancet"},{"issue":"5","key":"6628_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"2","key":"6628_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","volume":"8","author":"JH Choe","year":"2024","unstructured":"Choe JH, Yu T, Abramson JS, Abou-el-Enein M (2024) Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv 8(2):484\u2013496. https:\/\/doi.org\/10.1182\/bloodadvances.2023011793","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"6628_CR7","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2022-157309","volume":"140","author":"C Cui","year":"2022","unstructured":"Cui C, Feng C, Rosenthal N, Wade SW, Curry L, Fu C, Shah GL (2022) Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US). Blood 140(Supplement 1):2161\u20132162. https:\/\/doi.org\/10.1182\/blood-2022-157309","journal-title":"Blood"},{"key":"6628_CR8","unstructured":"Definitionshandbuch 2025 Band 5, InEK GmbH (2025) Retrieved 8 August 2025 from https:\/\/www.g-drg.de\/media\/files\/definitionshandbuch-2025\/definitionshandbuch-2025-band-5"},{"key":"6628_CR9","unstructured":"European Medicines Agency (2025). Columvi: EPAR - Product information. Retrieved 13 August 2026 from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/columvi-epar-product-information_en.pdf"},{"key":"6628_CR10","unstructured":"European Medicines Agency (2026c ). Tepkinly: EPAR - Product information. Retrieved 13 August 2026 from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepkinly-epar-product-information_en.pdf"},{"key":"6628_CR11","unstructured":"European Medicines Agency (2026a). Breyanzi: EPAR - Product information.Retrieved 13 August 2026 from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/breyanzi-epar-product-information_en.pdf"},{"key":"6628_CR12","unstructured":"European Medicines Agency (2026b). Yescarta: EPAR - Product information.Retrieved 13 August 2026 from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yescarta-epar-product-information_en.pdf"},{"issue":"5","key":"6628_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","volume":"60","author":"N Fabbri","year":"2023","unstructured":"Fabbri N, Mussetti A, Sureda A (2023) Second-line treatment of diffuse large B-cell lymphoma: evolution of options. Semin Hematol 60(5):305\u2013312. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.12.001","journal-title":"Semin Hematol"},{"issue":"1","key":"6628_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW (2011) Relapsed\/refractory diffuse large B-cell lymphoma. Hematology 2011(1):498\u2013505. https:\/\/doi.org\/10.1182\/asheducation-2011.1.498","journal-title":"Hematology"},{"issue":"03\/22","key":"6628_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.24945\/MVF.03.22.1866-0533.2416","volume":"15","author":"K Gehrke","year":"2022","unstructured":"Gehrke K, Th\u00f6nnes S, Lempfert S (2022) Analyse der Therapie- und Kostenstrukturen bei Patienten mit DLBCL in der GKV. Monit Versorgungsforschung 15(03\/22):77\u201384. https:\/\/doi.org\/10.24945\/MVF.03.22.1866-0533.2416","journal-title":"Monit Versorgungsforschung"},{"key":"6628_CR16","unstructured":"GKV-Spitzenverband (2025) Bundesbasisfallwert (BBFW). GKV-Spitzenverband. Retrieved 8 August 2025 from https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/krankenhaeuser\/budgetverhandlungen\/bundesbasisfallwert\/bundesbasisfallwert.jsp"},{"key":"6628_CR18","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (Ed.). (2023). Allgemeine Methoden: Version 7.0 (7.0). Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf"},{"key":"6628_CR17","unstructured":"Institut f\u00fcr das Entgeltsystem im Krankenhaus (InEK) (2023) InEK DatenBrowser. https:\/\/www.g-drg.de\/datenlieferung-gem.-21-khentgg\/inek-datenbrowser"},{"issue":"1","key":"6628_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon E, Arnason (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma 63(1):54\u201363. https:\/\/doi.org\/10.1080\/10428194.2021.1975188","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"6628_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/ejh.14095","volume":"111","author":"MS Kurte","year":"2023","unstructured":"Kurte MS, Siefen A, Jakobs F, Von Tresckow B, Reinhardt HC, Kron F (2023) Cost-effectiveness analysis of transplant\u2010ineligible relapsed or refractory diffuse large B\u2010cell lymphoma treatment options\u2014Experience of the efficiency frontier approach. Eur J Haematol 111(6):895\u2013908. https:\/\/doi.org\/10.1111\/ejh.14095","journal-title":"Eur J Haematol"},{"key":"6628_CR22","unstructured":"Lenz G, Chapuy B, Glass B, Keil F, Klapper W, Nickelsen M, Schmidberger H, Schmitt CA, Novak U, Wendtner C-M (2024), January Diffuses gro\u00dfzelliges B-Zell-Lymphom (Stand Januar 2024) [Connector]. Onkopedia. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/diffuses-grosszelliges-b-zell-lymphom"},{"issue":"7","key":"6628_CR23","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Mu\u00f1oz J, Farooq U, Van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Westin JR (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"issue":"7","key":"6628_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","volume":"22","author":"B Moertl","year":"2022","unstructured":"Moertl B, Dreyling M, Schmidt C, Hoster E, Schoel W, Bergwelt-Baildon MV, Berger K (2022) Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective. Clin Lymphoma Myeloma Leuk 22(7):474\u2013482. https:\/\/doi.org\/10.1016\/j.clml.2021.12.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6628_CR25","doi-asserted-by":"publisher","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy A, McSweeney P, Munoz J, Siddiqi T, Locke FL (2023) Five-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood blood2022018893. https:\/\/doi.org\/10.1182\/blood.2022018893","DOI":"10.1182\/blood.2022018893"},{"issue":"2","key":"6628_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40487-024-00265-8","volume":"12","author":"S Pacis","year":"2024","unstructured":"Pacis S, Bolzani A, Heuck A, Gossens K, Kruse M, Fritz B, Maywald U, Wilke T, Kunz C (2024) Epidemiology and real-world treatment of incident diffuse large B-cell lymphoma (DLBCL): a German claims data analysis. Oncol Therapy 12(2):293\u2013309. https:\/\/doi.org\/10.1007\/s40487-024-00265-8","journal-title":"Oncol Therapy"},{"issue":"3","key":"6628_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5045\/br.2021.2021107","volume":"56","author":"S-S Park","year":"2021","unstructured":"Park S-S, Kim H-J, Kim TY, Lee JY, Lee JH, Min GJ, Park S, Yoon J-H, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Kim D-W (2021) Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study. BLOOD Res 56(3):184\u2013196. https:\/\/doi.org\/10.5045\/br.2021.2021107","journal-title":"BLOOD Res"},{"issue":"11","key":"6628_CR28","doi-asserted-by":"publisher","first-page":"750e1","DOI":"10.1016\/j.jtct.2022.08.010","volume":"28","author":"M-A Perales","year":"2022","unstructured":"Perales M-A, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB (2022) The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 Trial. Transpl Cell Therapy 28(11):750e1\u2013750e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.08.010","journal-title":"Transpl Cell Therapy"},{"issue":"7","key":"6628_CR29","doi-asserted-by":"publisher","first-page":"e70417","DOI":"10.1002\/hem3.70417","volume":"10","author":"C Scheid","year":"2026","unstructured":"Scheid C, G\u00f6del P, Krone C, Carpinteiro E, Hallek M, Holtick U, Richardson T (2026) Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: first clinical insights with cilta\u2010cel in Germany. HemaSphere 10(7):e70417. https:\/\/doi.org\/10.1002\/hem3.70417","journal-title":"HemaSphere"},{"issue":"7","key":"6628_CR30","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1097\/HS9.0000000000000736","volume":"6","author":"D Skalt","year":"2022","unstructured":"Skalt D, Moertl B, Von Bergwelt-Baildon M, Schmidt C, Schoel W, B\u00fccklein V, Weiglein T, Dreyling M, Berger K (2022) Budget impact analysis of CAR T-cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Germany. HemaSphere 6(7):e736. https:\/\/doi.org\/10.1097\/HS9.0000000000000736","journal-title":"HemaSphere"},{"issue":"S3","key":"6628_CR31","doi-asserted-by":"publisher","first-page":"e3278692","DOI":"10.1097\/01.HS9.0000975996.32786.92","volume":"7","author":"J Westin","year":"2023","unstructured":"Westin J, Jacobson C, Chavez JC, Sureda A, Morschhauser F, Glass B, Dickinson M, Davies AJ, Flinn IW, Maloney D, Chamuleau M, Tees M, Xue A, Shahani S, Nikolajeva O, Kang J, Kaplan A, Schupp M, Miao H, Rich ES (2023) PB2319: ZUMA-23: a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. HemaSphere 7(S3):e3278692. https:\/\/doi.org\/10.1097\/01.HS9.0000975996.32786.92","journal-title":"HemaSphere"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06628-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:15:57Z","timestamp":1790867757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06628-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6628"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06628-0","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC Froitzheim, MS Kurte, K Hesse and F Kron are employees of VITIS Healthcare Group, which was sponsored by Gilead Sciences GmbH in connection with the development of this manuscript. K Gehrke and S Lempfert are employees of Institut f\u00fcr deskriptive Gesundheitsdatenanalyse OHG (DGDA), which was sponsored by Gilead Sciences GmbH in connection with the development of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"190"}}